TENAX THERAPEUTICS, INC.

TENX · Nasdaq · SIC 2834: Pharmaceutical Preparations
382
SEC Filings

Business Summary

Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies. Its prioritized product candidate is oral levosimendan (TNX-103), currently in two Phase 3 clinical trials (LEVEL and LEVEL-2) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). The company has also deprioritized a Phase 3 trial of imatinib for pulmonary hypertension. Both drugs are already approved in other indications worldwide. Tenax has no approved products currently on the market.

Next Earnings

Q2 FY2026 — expected 2026-09-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionTENXdiscussed_in_filing Healthcare & Bio
topic_mentionTENXdiscussed_in_filing Healthcare & Bio
topic_mentionTENXdiscussed_in_filing Healthcare & Bio
topic_mentionTENXdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-102025-12-310001193125-26-099393EDGAR47K words
2025-03-252024-12-310000950170-25-044398EDGAR—
2024-03-282023-12-310001654954-24-003827EDGAR—
2023-03-312022-12-310001654954-23-003945EDGAR—
2022-03-292021-12-310001654954-22-004036EDGAR—
2021-03-312020-12-310001654954-21-003641EDGAR—
2020-03-302019-12-310001654954-20-003498EDGAR—
2019-04-012018-12-310001654954-19-003861EDGAR—
2018-04-022017-12-310001654954-18-003517EDGAR—
2017-03-162016-12-310001654954-17-002098EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001193125-25-277793EDGAR14K words
2025-08-132025-06-300000950170-25-108063EDGAR—
2025-05-142025-03-310000950170-25-071395EDGAR—
2024-11-132024-09-300001654954-24-014262EDGAR—
2024-08-132024-06-300001654954-24-010456EDGAR—
2024-05-142024-03-310001654954-24-006228EDGAR—
2023-11-132023-09-300001654954-23-014168EDGAR—
2023-08-142023-06-300001654954-23-010758EDGAR—
2023-05-152023-03-310001654954-23-006566EDGAR—
2022-11-102022-09-300001654954-22-015030EDGAR—
2022-08-112022-06-300001654954-22-011073EDGAR—
2022-05-162022-03-310001654954-22-006980EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-100001654954-26-002072EDGAR1K words
2026-01-090001654954-26-000232EDGAR—
2025-12-170001654954-25-014059EDGAR—
2025-11-120001654954-25-012921EDGAR—
2025-09-160001654954-25-010792EDGAR—
2025-09-090001654954-25-010510EDGAR—
2025-08-130001654954-25-009510EDGAR—
2025-06-170001654954-25-007104EDGAR—
2025-05-140000950170-25-071382EDGAR—
2025-03-250000950170-25-044375EDGAR—

382 total filings indexed. 350 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

pulmonary-hypertension heart-failure-with-preserved-ejection-fraction-(hfpef) cardiopulmonary-therapeutics pharmaceutical-drug-development

Company Identity

CIK0000034956
TickerTENX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 017ade3f28e7f51d991af8cde2fa9160f4974f3e266822d41baa5245d9e8ba90
parent: 8cd633626a44fd35510b11eafa5cce5db6b68700b9971fb22947c3c068d17b7f
content hash: 1b76f7cad8fdd2fa7fffd1f11c08cc7aaad2c45bd1d74012193211471bbee1ae
signed: 2026-04-13T04:47:46.086Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf